Dysport and Jeuveau both compete with Botox, but they do it on different terms — and for an owner, comparing them is about fit and cost, not a clinical leaderboard.
This is general education for owners, not medical advice.
Injectables
Dysport vs Jeuveau: Two Neurotoxin Alternatives in Different Lanes
Both compete with Botox, but on different terms — diffusion profile versus value positioning. The owner's comparison is about fit and cost, not a clinical leaderboard.
1-YEAR MOVE
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
Get the free Inside MedSpa brief by email
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.
| Compared | Dysport | Jeuveau |
|---|---|---|
| Active | abobotulinumtoxinA | prabotulinumtoxinA |
| Dosing vs Botox | ~2.5:1 to 3:1 conversion | Closer to 1:1 |
| Positioning | Established, spread profile | Value alternative in the 1:1 lane |
| Loyalty program | Aspire (Galderma) | Evolus Rewards |
Two Botox alternatives with different pitches — one on its spread profile, one on value. The right one depends on your patients and your loaded-cost math.
Different lanes
Dysport (abobotulinumtoxinA) is established, noted for its spread/diffusion profile, and doses at roughly a 2.5:1 to 3:1 conversion from Botox. Jeuveau (prabotulinumtoxinA) doses closer to 1:1 and is positioned as a value alternative in that lane. So they're not really head-to-head on identical terms — one competes on an established profile and different dosing, the other on value in the 1:1 lane.
The owner's decision
The choice depends on patient fit, loaded-cost math (accounting for the dosing conversion and rebate/loyalty capture), and your portfolio and loyalty strategy — they sit in different loyalty ecosystems (Aspire for Dysport, Evolus Rewards for Jeuveau). As always, convert to loaded cost per equivalent treatment before comparing price, and let your injectors weigh in on clinical feel.
What to do
- Compare on loaded cost per equivalent treatment, accounting for the different dosing conversions.
- Factor in the different loyalty programs (Aspire vs Evolus Rewards) and your portfolio strategy.
- Match to patient fit and your market, with clinical input from injectors.
Frequently asked questions
What's the difference between Dysport and Jeuveau?
Both are neurotoxins competing with Botox — Dysport (abobotulinumtoxinA) doses at roughly a 2.5:1 to 3:1 conversion and is noted for its spread profile, while Jeuveau (prabotulinumtoxinA) doses closer to 1:1 and is positioned as a value alternative. They sit in different competitive lanes. This is general education, not medical advice.
Which should a practice carry?
It depends on patient fit, loaded-cost math (accounting for dosing conversion and rebates/loyalty), and your portfolio strategy. They have different loyalty programs (Aspire vs Evolus Rewards), which factors into the decision.
Business information, not medical or legal advice. Verify product status at FDA.gov.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.